TOSCA - pubblicazioni

Three Or Six Colon Adjuvant

A RANDOMIZED TRIAL INVESTIGATING THE ROLE OF FOLFOX-4 OR XELOX (3 VERSUS 6 MONTHS) REGIMEN DURATION AND BEVACIZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH STAGE II/III COLON CANCER

· LETTER COMMENT AND RESPONSE RISK-BENEFIT TOSCA

Scarica il file  

· ASSESSMENT OF DURATION AND EFFECTS OF 3 VS 6 MONTHS OF ADJUVANT CHEMOTHERAPY IN

  HIGH-RISK STAGE II COLORECTAL CANCER: A SUBGROUP ANALYSIS OF THE TOSCA RANDOMIZED

  CLINICAL TRIAL

Scarica il file  

· KHORANA SCORE AND THROMBOEMBOLIC RISK IN STAGE II - III COLORECTAL CANCER

  PATIENTS: A POST HOC ANALYSIS FROM THE ADJUVANT TOSCA TRIAL

Scarica il file  

· PREDICTIVE IMPACT OF MUCINOUS TUMORS ON THE CLINICAL OUTCOME IN PATIENTS

  WITH POORLY DIFFERENTIATED, STAGE II COLON CANCER: A TOSCA SUBGROUP ANALYSIS

Scarica il file  

· DURATION OF OXALIPLATIN - CONTAINING ADJUVANT.

  THERAPY FOR STAGE III COLON CANCER: ASCO CLINICAL PRACTICE GUIDELINE

Scarica il file  

· IMPACT OF METFORMIN USE AND DIABETIC STATUS DURING ADJUVANT FLUOROPYRIMIDINE -

  OXALIPLATIN CHEMOTHERAPY ON THE OUTCOME OF PATIENTS WITH RESECTED COLON CANCER:

  A TOSCA STUDY SUBANALYSIS

Scarica il file  

· TOSCA IDEA: RIFLESSIONI E COMMENTI

Scarica il file  

· FOLFOX OR CAPOX IN STAGE II TO III COLON CANCER: EFFICACY RESULTS OF THE ITALIAN THREE

  OR SIX COLON ADJUVANT TRIAL

Scarica il file  

· THE HARD ROAD TO DATA INTERPRETATION: THREE OR SIX MONTHS OF ADJUVANT

  CHEMOTHERAPIE FOR PATIENTS WITH STAGE III COLON CANCER?

Scarica il file  

· DURATION OF ADJUVANT CHEMOTHERAPY FOR STAGE III COLON CANCER

Scarica il file  

· PHASE III TRIAL COMPARING 3-6 MONTHS OF ADJUVANT FOLFOX4/XELOX IN STAGE II-III COLON     CANCER: SAFETY AND COMPLIANCE IN THE TOSCA TRIAL

Scarica il file  

· GENETIC MARKERS FOR TOXICITY OD ADJUVANT OXALIPLATIN AND FLUOROPYRIMIDINES IN THE   PHASE III TOSCA TRIAL IN HIGH-RISK COLON CANCER PATIENTS

Scarica il file  

· DIHYDROPYRIMIDINE DEHYDROGENASE PHARMACOGENETICS FOR PREDICTING  

  FLUOROPYRIMIDINE-RELATED TOXICITY IN THE RANDOMIZED, PHASE III ADJUVANT TOSCA TRIAL

  IN HIGH-RISK COLON CANCER PATIENTS

Scarica il file  

FONDAZIONE
GISCAD

GRUPPO ITALIANO PER LO STUDIO DEI 

CARCINOMI DELL'APPARATO DIGERENTE

SEDE

Via Gattinoni, 4

20043 Vanzago (MI)

CONTATTI

Tel. 02 84968409

ufficio.operativo@giscad.it

© 2018 Fondazione GISCAD - P.IVA 05396970963